Natriuretic peptides, respiratory disease, and the right heart

Chest

Volumn 126, Issue 4, 2004, Pages 1330-1336

  Lok, Bin Yap ^a   Mukerjee, Dev ^b   Timms, Peter M ^c   Ashrafian, Houman ^d   Coghlan, John Gerard ^b  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d EALING HOSPITAL   (United Kingdom)

Author keywords

Natriuretic peptide; Pulmonary arterial hypertension; Right ventricular dysfunction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP;

COMPARATIVE STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HEART HYPERTROPHY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE PRESSURE; HUMAN; KNOCKOUT MOUSE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; MOLECULAR MECHANICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

EID: 6344250896     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.4.1330     Document Type: Article

References (75)

1. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 1985; 230:767-770
2. King L, Wilkins MR. Natriuretic peptide receptors and the heart. Heart 2002; 87:314-315
3. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998; 135(suppl):914-923
4. Maisel A, Krishnaswamy P, Nowak R, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167
5. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322
6. Yandle TG. Biochemistry of natriuretic peptides. J Intern Med 1994; 235:561-576
7. Sagdala GA. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 2001; 38:83-93
8. Yan W, Wu F, Morser J, et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000; 97:8525-8529
9. Hunt PJ, Espiner EA, Nicholls MG, et al. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997; 18:1475-1481
10. Wu F, Yan W, Pan J, et al. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem 2002; 277:16900-16905
11. Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001; 15:2187-2195
12. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986; 324: 473-476
13. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87:464-469
14. Globits S, Frank H, Pacher B, et al. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am Heart J 1998; 135:592-597
15. Montorsi P, Tonolo G, Polonia J, et al. Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension 1987; 10:570-576
16. Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci (Lond) 1992; 83:437-444
17. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:274-279
18. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93:1963-1969
19. Yasue H, Yoshimura M, Sumida A, et al. Localization of mechanism of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203
20. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92:29-34
21. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28:22-30
22. Jensen KT, Carstens J, Ivarsen P, et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma: reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997; 57:529-540
23. Wallen T, Landahl S, Hedner T, et al. Brain natriuretic peptide in an elderly population. J Intern Med 1997; 242: 307-311
24. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994
25. Lang CC, Coutie WJ, Struthers AD, et al. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic pulmonary disease. Clin Sci (Lond) 1992; 83:529-533
26. Morrison LK, Harrison A, Krishnaswamy PL, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea. J Am Coll Cardiol 2002; 39:202-205
27. Bando M, Ishii Y, Sugiyama Y, et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93:507-514
28. Cabanes L, Richaud-Thiriez B, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120:2047-2050
29. Ishii J, Nomura M, Ito M, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000; 301:19-30
30. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 19;343:440-444
31. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type Natriuretic Peptide in the emergency department. Acad Emerg Med 2003; 10:198-204
32. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31:202-208
33. Wiedemann R, Ghofrani HA, Weissmann N, et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. J Am Coll Cardiol 2001; 38:1130-1136
34. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870
35. Tulevski II, Hirsch A, Sanson BJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001; 86:1193-1196
36. Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22:649-653
37. ten Wolde M, Tulevski II, Mulder JW, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107:2082-2084
38. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547
39. Nagaya N, Ando M, Oya H, et al. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002; 74:180-184
40. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161(suppl):487-492
41. Mariano-Goulart D, Eberle MC, Boudousq V, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail 2003; 5:481-488
42. Tulevski I, Groenink M, Evan der Wall E et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86:27-30
43. Fischer Y, Filzmaier K, Stiegler H, et al. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. Clin Chem 2001; 47:591-594
44. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141:367-374
45. Liang F, Kovacic-Milivojevic B, Chen S, et al. Signaling mechanisms underlying strain-dependent brain natriuretic peptide gene transcription. Can J Physiol Pharmacol 2001; 79:640-645
46. Liang F, Lu S, Gardner DG. Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase. Hypertension 2000; 35(suppl):188-192
47. Peter Goetze J, Kastrup J, Rehfeld JF, et al. The paradox of increased natriuretic hormones in congestive heart failure patients: does the endocrine heart also fail in heart failure? Eur Heart J 2003; 24:1471-1472
48. Hasegawa K, Fujiwara H, Itoh H, et al. Light and electron microscopic localization of brain natriuretic peptide in relation to atrial natriuretic peptide in porcine atrium: immunohistocytochemical study using specific monoclonal antibodies. Circulation 1991; 84:1203-1209
49. de Bold AJ, Ma KK, Zhang Y, et al. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 2001; 79:705-714
50. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000; 46:1529-1534
51. Redondo J, Bishop JE, Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol 1998; 124:1455-1462
52. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000; 97:4239-4244
53. Horio T, Nishikimi T, Yoshihara F, et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35(suppl): 19-24
54. Sun JZ, Chen SJ, Li G, et al. Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice. Am J Physiol Lung Cell Mol Physiol 2000; 279:L511-L519
55. Klinger JR, Warburton RR, Pietras LA, et al. Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice Am J Physiol Lung Cell Mol Physiol 1999; 276:L878-L874
56. Klinger JR, Warburton RR, Pietras LA, et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2002; 282:H58-H65
57. Kuhn M, Holtwick R, Baba HA, et al. Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart 2002; 87:368-374
58. Adnot S, Chabrier PE, Brun-Buisson C, et al. Atrial natriuretic factor attenuates the pulmonary presser response to hypoxia. J Appl Physiol 1988; 65:1975-1983
59. Klinger JR, Pietras L, Warburton R, et al. Reduced oxygen tension increases atrial natriuretic peptide release from atrial cardiocytes. Exp Biol Med (Maywood) 2001; 226:847-853
60. Nakanishi K, Tajima F, Itoh H, et al. Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia-induced pulmonary hypertension in rats. Virchows Arch 2001; 439:808-817
61. Klinger JR, Warburton RR, Pietras L, et al. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats J Appl Physiol 1998; 84:1646-1652
62. Zhao L, Long L, Morrell NW, et al. NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 1999; 99:605-607
63. Schermuly RT, Weissmann N, Enke B, et al. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon co-application. Am J Respir Cell Mol Biol 2001; 25:219-225
64. Eddahibi S, Raffestin B, Le Monnier de Gouville AC, et al. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br J Pharmacol 1998; 125:681-688
65. Kodama K, Adachi H. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 1999; 290:748-752
66. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895-900
67. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-164
68. Zhao L, Mason NA, Strange JW. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 2003; 107:234-237
69. Cargill RI, Lipworth BJ. Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol 1995; 40:585-590
70. Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale: hemodynamic and endocrine effects. Chest 1996; 110:1220-1225
71. Elkayam U, Akhter MW, Tummala P, et al. Nesiritide: a new drug for the treatment of decompensated heart failure. J Cardiovasc Pharmacol Ther 2002; 7:181-194
72. Colucci WS. Nesiritide for the treatment of decompensaed heart failure. J Card Fail 2001; 7:92-100
73. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287:1531-1540
74. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 2000; 356:608-609
75. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926